The global automated cell sorter market size is likely to be valued at US$3.4 billion in 2026, and is expected to reach US$6.6 billion by 2033, growing at a CAGR of 9.9% during the forecast period from 2026 to 2033, driven by the continued expansion of life sciences research, the increasing adoption of cell therapies as a key biopharmaceutical modality, and the growing automation of cell biology workflows across research, clinical, and biomanufacturing applications worldwide.

Driver - Rapid Expansion of Cell Therapy and Immunotherapy Research and Manufacturing

The emergence of cell-based therapies, particularly chimeric antigen receptor T cell (CAR-T) therapies, natural killer (NK) cell therapies, tumor-infiltrating lymphocyte (TIL) therapies, and regulatory T cell (Treg) therapies as a transformative modality in oncology and autoimmune disease has created a new and rapidly growing high-value application for automated cell sorters in both research and manufacturing contexts.

The global cell therapy pipeline encompassing hundreds of ongoing clinical trials across CAR-T, NK cell, mesenchymal stem cell, and other cell therapy modalities represents a sustained and growing source of instrument and consumable demand for automated cell sorters across both academic research institutions running early-phase programs and biopharmaceutical companies scaling from clinical to commercial manufacturing.

Restraint - Regulatory Complexity for Clinical and GMP Cell Sorting Applications

The use of automated cell sorters in clinical and GMP cell therapy manufacturing settings requires compliance with FDA 21 CFR Part 820 Quality System Regulations, EMA GMP Annex 1, and ISO 13485 medical device quality management standards, a regulatory framework that imposes significant instrument qualification, software validation, process change control, and batch record documentation requirements that substantially increase the cost and complexity of deploying automated cell sorters in clinical manufacturing environments relative to research use.

The requirement for closed-system, sterile sorting configurations that prevent contamination of sorted cell products, and the validation burden associated with qualifying instrument cleaning procedures, sort purity, viability, and recovery specifications across manufacturing process development and validation studies, adds development timelines and costs that can deter cell therapy developers from incorporating automated sorting into commercial manufacturing processes where alternative cell selection methods offer lower regulatory complexity.

Opportunity - GMP-Compliant Automated Cell Sorting for Cell Therapy Manufacturing

The rapid scale-up of cell therapy commercial manufacturing represents the most significant near-term growth opportunity for premium automated cell sorter platforms specifically engineered for GMP compliance. Current commercial CAR-T cell manufacturing processes require multiple cell selection and sorting steps. The increasing number of approved cell therapy products entering commercial production and the expanding pipeline of next-generation allogeneic cell therapies are driving demand for closed-system, GMP-validated automated cell sorting instruments for industrial-scale sorting of donor T cells and NK cells.

Miltenyi Biotec's CliniMACS Prodigy, which integrates closed-system magnetic cell separation with cultivation and formulation, and BD's FACSymphony S6 with biosafety cabinet integration represent the current generation of GMP-positioned automated cell sorting platforms. The commercial cell therapy manufacturing sector's requirement for scalable, validated, and regulatorily defensible cell sorting workflows creates a high-value instrument category with strong service contract attachment rates that are substantially more valuable per instrument installed than research-grade equivalents.

Product Type Insights

High-throughput sorters are forecast to dominate the product type, accounting for  46% of the total share in 2026, due to their ability to process large cell volumes at high speed and precision, making them essential for drug discovery, immunology research, and large-scale functional screening applications. BD Biosciences offers the BD FACSymphony™ S6 Cell Sorter, a high-throughput cell sorting platform capable of analyzing up to 50 parameters and sorting up to six cell populations simultaneously.

Integrated sorters are likely to be the fastest-growing product type, driven by the growing demand from cell therapy manufacturing and clinical cell processing for closed-system, automated cell sorting instruments that integrate selection, washing, concentration, and formulation steps within a single sterile, GMP-compliant processing workflow. Miltenyi Biotec developed the CliniMACS Prodigy® Platform, a fully integrated, closed-system, GMP-compliant cell processing platform widely used in cell and gene therapy manufacturing.

Technology Insights

Optical sorting is estimated to dominate the technology segment, accounting for 44% of market revenue in 2026. FACS technology uses laser-based cell analysis and electrostatic sorting to separate multiple cell populations simultaneously, delivering high resolution, purity, and sorting accuracy. Sony Biotechnology offers the ID7000™ Spectral Cell Analyzer and FP7000™ Spectral Cell Sorter, advanced FACS-based platforms that use laser-driven fluorescence detection to identify and sort multiple cell populations with high purity and accuracy.

Microfluidics is likely to be the fastest-growing technology segment, driven by the development of miniaturized microfluidic cell sorting platforms that offer gentle, high-viability cell separation, reduced aerosol risks, and compact point-of-care-compatible designs, making them suitable for applications where conventional FACS systems are impractical. Cellenion (BICO Group) developed the CYCLONE™+ microfluidic single-cell isolation platform, which uses gentle microfluidic handling to isolate and dispense viable cells with minimal stress.

Application Insights

Research laboratories are anticipated to dominate the application segment, accounting for  42% of market revenue in 2026. Academic and government research laboratories form the core customer base for automated cell sorters, using these systems across immunology, cancer, stem cell, and infectious disease research, representing the largest global installed base. Fred Hutchinson Cancer Center operates the Flow Cytometry Core Facility, which provides advanced cell sorting services using high-parameter FACS instruments for cancer, immunology, stem cell, and infectious disease research.

Pharmaceuticals are likely to be the fastest-growing application segment, driven by expanding cell therapy development programs, increasing use of automated cell sorting in drug screening, and growing adoption of high-content and single B cell sorting for therapeutic antibody discovery. AbbVie uses single B-cell screening and cell-sorting technologies in its antibody discovery programs to identify and develop novel therapeutic antibodies for immunology and oncology applications.

End-user Insights

Academic institutes are expected to lead the end-user segment, accounting for 35% of revenue in 2026. Universities and academic medical centers are major users of high-end FACS cell sorters, leveraging centralized flow cytometry core facilities and shared infrastructure models to maximize instrument utilization and justify capital investments. Stanford University operates the Stanford Shared FACS Facility, a centralized flow cytometry core that provides researchers access to advanced cell analyzers and high-end cell sorters.

Biotechnology companies are likely to be the fastest-growing end-user segment, fueled by the global proliferation of cell therapy, gene therapy, and immuno-oncology biotechnology companies that deploy automated cell sorting across research, process development, and GMP manufacturing applications. Caribou Biosciences, a clinical-stage biotechnology company focused on CRISPR-based cell therapies, utilizes advanced cell processing and sorting technologies in the development and manufacturing of allogeneic CAR-T cell therapies.

North America Automated Cell Sorter Market Trends

North America is projected to hold 40% of the market revenue in 2026, representing the largest regional market. The region's leadership reflects the world's largest life science research funding base, the most commercially advanced cell therapy manufacturing ecosystem, and the highest concentration of biotechnology companies and academic medical centers deploying automated cell sorting across research and manufacturing applications.

U.S Automated Cell Sorter Market Insights

The U.S. is estimated to command 88% of North America revenue share in 2026, driven by NIH research funding exceeding US$47 billion annually, a strong presence of cell therapy biotech companies across major biopharma hubs such as San Francisco Bay Area, Boston/Cambridge, and San Diego, and FDA accelerated approval pathways that support the commercialization of cell therapies, boosting demand for automated cell sorting in both research and GMP manufacturing.

Canada Automated Cell Sorter Market Insights

Canada is anticipated to account for 12% of North American market share in 2026, supported by its strong academic research institutions including University of Toronto, McGill University, and BC Cancer Agency with well-established flow cytometry core facilities, the Canadian Institutes of Health Research (CIHR) funding supporting life science research programs, and the growing Canadian cell therapy research and early-stage biotech ecosystem in Toronto, Montreal, and Vancouver.

Europe Automated Cell Sorter Market Trends

Europe is likely to hold 27% of the global market revenue in 2026. The region's market is characterized by strong academic research infrastructure, well-funded national health research systems, a growing cell therapy biotech sector, and increasing adoption of automated cell sorting in clinical diagnostic and blood banking applications.

Germany Automated Cell Sorter Market Trends

Germany is expected to command around 25% of Europe's market revenue in 2026, driven by its world-class academic research infrastructure, including the Max Planck Society, Helmholtz Association, and Deutsche Forschungsgemeinschaft (DFG)-funded university research centers deploying automated cell sorters across immunology, hematooncology, and stem cell research programs.

U.K. Automated Cell Sorter Market Trends

The U.K. is projected to hold 20% of regional market share in 2026, supported by the Wellcome Trust, Cancer Research UK, and Medical Research Council funding sustaining high-quality life science research at institutions including the Francis Crick Institute, Sanger Institute, and Oxford and Cambridge universities that operate world-class flow cytometry facilities.

Asia Pacific Automated Cell Sorter Market Trends

Asia Pacific is likely to be the fastest-growing regional market, projected to expand at a CAGR of 11.4% from 2026 to 2033. The region's growth reflects the rapid expansion of life science research investment, the development of domestic cell therapy research and manufacturing programs, and the growing adoption of automated cell sorting in clinical laboratory settings across China, Japan, South Korea, and India.

China Automated Cell Sorter Market Trends

China is projected to command 38% of Asia Pacific revenue in 2026, driven by rising government funding through the National Natural Science Foundation of China, expanding cell therapy research with over 400 CAR-T clinical trials, and growing adoption of automated cell sorting by domestic cell therapy manufacturers.

Japan Automated Cell Sorter Market Trends

Japan is estimated to hold 24% of the regional market share in 2026, supported by strong government life science research funding through the Japan Agency for Medical Research and Development, a favorable regenerative medicine regulatory framework, and domestic cell sorter manufacturing by Sony Biotechnology, which benefits from established local market relationships.

The global automated cell sorter market features a competitive landscape of life science instrument companies spanning diversified diagnostics and life science tool corporations, dedicated flow cytometry specialists, and immunomagnetic cell separation technology companies.

BD Biosciences maintains the world's largest installed base of cell sorters through its FACSAria and FACSMelody product families, and its BD Rhapsody single-cell genomics platform integration with FACS sorting is establishing a new competitive dimension at the intersection of cell sorting and single-cell sequencing. Beckman Coulter Life Sciences' MoFlo Astrios and CytoFLEX SRT sorters compete directly with BD in the high-speed, multi-parameter research sorter market segment.

Key Industry Developments:

• In May 2026, Bionomous launched Sortivo™, an automated benchtop platform for the screening, sorting, and plating of complex biological entities, at SLAS Europe in Vienna, Austria. The company designed the platform to handle zebrafish embryos, organoids, and other delicate samples ranging from 300 µm to 2 mm. Sortivo enabled researchers to replace labor-intensive manual workflows and supported the adoption of New Approach Methodologies (NAMs) in toxicology and pre-clinical research.
• In May 2025, BD (Becton, Dickinson and Company) announced the global commercial launch of the world's first cell analyzer featuring spectral and real-time cell imaging technologies. The company enabled researchers to uncover deeper cellular insights and dynamics that were previously difficult to detect in flow cytometry experiments while improving ease of use and throughput.